-
Mashup Score: 1P2Y12 inhibition in high bleeding risk patients: making the right decision in a complex setting - 7 month(s) ago
We read with great interest the SWEDEHEART report by Tjerkaski et al.1 regarding the comparison of ticagrelor vs. clopidogrel in patients with myocardial infarc
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis - 7 month(s) ago
American Journal of Cardiovascular Drugs – The worldwide prevalence of chronic kidney disease (CKD) has significantly increased in the past decades. Scientific reports have shown CKD to be an…
Source: link.springer.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2
AbstractAims. To characterize and follow patients with ST-segment elevation myocardial infarction (STEMI) at high bleeding risk (HBR) according to the predictin
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2
Aspirin is the only antiplatelet agent with a Class I recommendation for long-term prevention of cardiovascular events in patients with coronary arter…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention - 2 year(s) ago
This 3-year follow-up of a randomized clinical trial assesses the long-term safety and efficacy of P2Y12 inhibitor monotherapy following 3 months of dual antiplatelet therapy after percutaneous coronary intervention.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 11P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials - 2 year(s) ago
AbstractAim. To compare the efficacy and safety of P2Y12 inhibitor or aspirin monotherapy for secondary prevention in patients with atherosclerotic cardiovascul
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 6P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials - 2 year(s) ago
AbstractAim. To compare the efficacy and safety of P2Y12 inhibitor or aspirin monotherapy for secondary prevention in patients with atherosclerotic cardiovascul
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 4P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials - 2 year(s) ago
AbstractAim. To compare the efficacy and safety of P2Y12 inhibitor or aspirin monotherapy for secondary prevention in patients with atherosclerotic cardiovascul
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials - 2 year(s) ago
AbstractAim. To compare the efficacy and safety of P2Y12 inhibitor or aspirin monotherapy for secondary prevention in patients with atherosclerotic cardiovascul
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 4Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis - 2 year(s) ago
AbstractAim. Optimal dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) intends
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
#P2Y12i in #HBR patients: making the right decision. #DAPT #SAPT https://t.co/opGpPOAsim